{
  "docId": "019de071-eb84-776b-8e7d-ce40a476afec",
  "docSlug": "ee62a94395a2a2b10c5eb93465b3bf02",
  "documentTitle": "Kymera | Investor Day Presentation Deck | 105 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 64,
  "pageCount": 105,
  "prevPage": 63,
  "nextPage": 65,
  "slideType": "other",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a process flow diagram to show the progression from initial dose levels (DL1, DL2, DLx) to expansion cohorts for various cancer types and combination therapies.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de071-eb84-776b-8e7d-ce40a476afec/64",
  "deckHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec",
  "deckJsonHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec.json",
  "deckAnchorHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec#slide-64",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.66,
        "x": 0.32,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Flowchart showing dose escalation (DL1, DL2, DLx) leading to MTD/RP2D expansion cohorts for PTCL, CTCL, LGL-L, Solid Tumors, and Combination Expansion.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7abe36f2-acb5-4831-a26f-ca72b335b4c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.28,
        "x": 0.03,
        "y": 0.16
      },
      "kind": "list",
      "text": "Key Eligibility Criteria: R/R B-cell lymphoma, Advanced solid tumors. Primary Objective: Evaluate safety, PK/PD. Study Endpoints: Safety, PK, Exploratory STAT3 knockdown.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "53c5a99d-0523-4b01-9930-e5196e5f705a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.61,
        "x": 0.195,
        "y": 0.03
      },
      "kind": "title",
      "text": "KT-333: Clinical Study Design and Objectives",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4b70a0a-27d5-4be5-ac9a-2fc4a0aa38f1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "03d429bd-3999-4c8f-a957-fd3fe71f2644",
      "evidence": "The slide uses a flow diagram to represent the clinical trial progression.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}